Nanoparticles targeting cancer cells

Nanoparticles: The Tiny Tech Revolutionizing Cancer Treatment and Beyond

Samir D’Costa monogram
Samir D’Costa in Health & Wellness November 2026 • 4 min read.

"Exploring the innovative applications of nanoparticles in drug delivery, diagnostics, and regenerative medicine."


Nanotechnology is rapidly advancing, offering unprecedented opportunities to revolutionize medicine. At the forefront of this revolution are nanoparticles—tiny particles, measured in billionths of a meter, with unique properties that make them ideal for a variety of biomedical applications.

From targeted drug delivery to enhanced diagnostics and regenerative medicine, nanoparticles are showing promise in addressing some of the most challenging healthcare problems. Their ability to interact with biological systems at the cellular and molecular level opens up new avenues for treating diseases and improving patient outcomes.

This article explores recent research highlighting the diverse applications of nanoparticles, focusing on their potential to transform cancer treatment, neural regeneration, and glucose monitoring for diabetes management. We’ll delve into the science behind these innovations and examine the potential impact on healthcare.

AI Search Multiple angles on this topic

Clinical Progress and Continuing Need

A 2024 review notes that, despite progress in patient care, the global incidence of various cancer types continues to rise. It describes nanotechnology as a promising approach for cancer diagnosis and treatment, with safer and more efficient anti-cancer treatments remaining an area of interest. Other reviews discuss nanoparticle types, targeting mechanisms, and approved nanotherapeutics for cancer treatment. The NCI identifies translation of research into clinical diagnosis and treatment as the true measure of nanotechnology’s success in medicine and oncology.

Targeted Cancer Therapy: Nanoparticles Deliver the Punch

Nanoparticles targeting cancer cells

One of the most promising applications of nanoparticles is in targeted drug delivery for cancer therapy. Traditional chemotherapy often affects healthy cells along with cancerous ones, leading to significant side effects. Nanoparticles can be engineered to selectively target cancer cells, delivering therapeutic drugs directly to the tumor site while sparing healthy tissue.

Researchers are exploring various strategies for nanoparticle-based drug delivery, including:

  • Superparamagnetic Iron Oxide Nanoparticles (SPIONs): These nanoparticles can be guided to the tumor site using external magnetic fields. When combined with drugs like chlorin e6 (Ce6), SPIONs can enhance photodynamic therapy (PDT), a treatment that uses light to activate drugs and destroy cancer cells.
  • Hyaluronic Acid Nanoparticles: These nanoparticles can target CD44 receptors, which are often overexpressed on cancer cells. By loading these nanoparticles with drugs like doxorubicin, researchers can selectively kill cancer cells while minimizing damage to healthy cells.
  • Polypeptide Complex Micelles: These micelles are designed to respond to specific conditions within the tumor environment, such as high glucose levels. By complexing phenylboronic acid (PBA)-functionalized polypeptides with dopamine-modified polypeptides, researchers can create micelles that release drugs in response to changes in glucose concentration.
AI Search Multiple angles on this topic

Beyond Drug Delivery

The National Cancer Institute says research into nanotechnology-based cancer therapy extends beyond drug delivery. It also includes creating new therapeutics that are possible only because of the properties of nanomaterials. This points to a broader research role for nanotechnology than serving solely as a vehicle for existing drugs.

Targeting Strategies and Combination Approaches

A review comparing passive and active nanoparticle targeting considers their relevance to cancer theranostics. Another review describes combination therapy using nanoparticles and photosensitive therapy as a potentially more successful approach than standalone therapies for breast cancer. The available sources also describe research into cancer stem cell therapy, DNA/RNA-based immunomodulation, tumor-microenvironment alteration, and cell-membrane-mediated biomimetic approaches. One review reports more than 69,000 publications on nanoparticle-based cancer treatments over the past decade, indicating growing research interest.

These approaches hold immense potential for improving the efficacy and reducing the toxicity of cancer treatments. By precisely targeting cancer cells, nanoparticles can deliver higher doses of drugs directly to the tumor, leading to better outcomes and fewer side effects for patients.

The Future is Nano

Nanoparticle technology represents a paradigm shift in medicine, offering the potential to diagnose, treat, and prevent diseases in ways never before imagined. As research continues to advance, we can expect to see even more innovative applications of nanoparticles emerge, transforming healthcare and improving the lives of patients worldwide.

AI Search Multiple angles on this topic

Theranostics: Promise and Challenges

A comprehensive review examines cancer theranostics, which combines diagnostic and therapeutic methods to customize cancer treatment. It analyzes the attributes and uses of different nanoparticle types, along with the difficulties associated with them. The review presents nanotechnology as a way to bring diagnosis and treatment together, while emphasizing that challenges remain.

Clinical Translation Amid Cancer Complexity

Cancer remains a global health challenge because of its complex pathophysiology and resistance to conventional treatments. Reviews of nanoparticle cancer therapy cover different particle types and targeting mechanisms, and identify clinical translation as an area with both advantages and challenges. The sources describe nanotechnology as a basis for innovative therapeutic platforms, while highlighting the difficulty of bringing these approaches into clinical use.

What the nanoparticle delivery figures mean in context

  • about 0.7% of injected doseA preclinical-data meta-analysis estimated that a median of about 0.7% of the injected nanoparticle dose reached target tumors. This is a share of the dose, not a measure of tumor response or patient benefit.[1]
  • 0.9%; 0.6%In a preclinical comparison, median tumor accumulation was 0.9% of the injected dose for actively targeted particles and 0.6% for passively targeted particles.[2]

What cancer nanoparticle reports show-and do not show

These delivery estimates suggest that getting particles to a tumor, and getting them to interact with cancer cells, are distinct steps. Tumor arrival alone therefore does not establish how much treatment reaches the cells it is intended to affect.[1] [3]

Strong results in preclinical cancers have not reliably translated into better clinical efficacy, and nanomedicines may not increase drug accumulation in human tumors compared with free drugs. The evidence describes a gap between promising delivery designs and demonstrated effects in people.[4]

Nanoparticles also change after injection: plasma proteins can coat their surfaces and alter how they interact with the biological environment. Drug distribution within a tumor can be uneven, so some tumor cells may not receive enough drug even when treatment is present elsewhere.[3] [5]

What evidence could resolve delivery gaps

  • Do preclinical differences in accumulation between active and passive targeting persist in human tumors, where nanomedicines may not increase drug accumulation over free drugs?[2] [4]
  • How much do protein coatings and uneven intratumoural distribution affect the amount of drug that reaches cancer cells?[3] [5]
  • Which nanoparticle design features, if any, can produce clinical efficacy consistently despite the failures seen in translation from preclinical cancers?[4]

Sources

  1. Progress and challenges towards targeted delivery of cancer therapeutics (pmc.ncbi.nlm.nih.gov)
  2. Overcoming Physiological Barriers to Nanoparticle Delivery—Are We There Yet? (pmc.ncbi.nlm.nih.gov)
  3. Towards principled design of cancer nanomedicine to accelerate clinical translation (pmc.ncbi.nlm.nih.gov)
  4. What Went Wrong with Anticancer Nanomedicine Design and How to Make It Right. (pubs.acs.org)
  5. Spatial heterogeneity of nanomedicine investigated by multiscale imaging of the drug, the nanoparticle and the tumour environment (pmc.ncbi.nlm.nih.gov)

About this Article -

Written with AI assistance from published research, and reviewed by the Mystum team. See our About page for more information.

Everything You Need To Know

1

What are nanoparticles and how are they used in medicine?

Nanoparticles are incredibly small particles, measured in billionths of a meter, that are being used in various biomedical applications. They possess unique properties that allow them to interact with biological systems at a cellular and molecular level. This characteristic is why they are suitable for drug delivery, diagnostics, and regenerative medicine. Their size and properties make them ideal for targeting specific cells and tissues.

2

Why is targeted drug delivery using nanoparticles important for cancer treatment?

Targeted drug delivery using nanoparticles is significant because it can improve the efficacy of cancer treatments while reducing side effects. Traditional chemotherapy affects both healthy and cancerous cells. Nanoparticles are designed to target cancer cells selectively, delivering drugs directly to the tumor site. This allows for higher drug concentrations at the tumor site and minimizes exposure of healthy tissues, leading to better patient outcomes. The use of Superparamagnetic Iron Oxide Nanoparticles (SPIONs), Hyaluronic Acid Nanoparticles, and Polypeptide Complex Micelles are some examples of how this is achieved.

3

How do Superparamagnetic Iron Oxide Nanoparticles (SPIONs) work in cancer therapy?

Superparamagnetic Iron Oxide Nanoparticles (SPIONs) are a type of nanoparticle that can be guided to a tumor site using external magnetic fields. When combined with drugs like chlorin e6 (Ce6), SPIONs can enhance photodynamic therapy (PDT). This therapy uses light to activate the drug and destroy cancer cells. The external magnetic field helps to concentrate the SPIONs, and thus the drug, at the tumor site, improving the therapy's effectiveness.

4

How do Hyaluronic Acid Nanoparticles target cancer cells?

Hyaluronic Acid Nanoparticles target cancer cells by interacting with CD44 receptors, which are frequently overexpressed on cancer cells. By loading these nanoparticles with drugs like doxorubicin, they can selectively kill cancer cells while minimizing damage to healthy cells. This approach improves treatment efficacy and reduces the adverse effects associated with traditional cancer therapies.

5

How do Polypeptide Complex Micelles work for drug delivery?

Polypeptide Complex Micelles are designed to respond to conditions within the tumor environment, such as high glucose levels. Researchers can create micelles that release drugs in response to changes in glucose concentration by complexing phenylboronic acid (PBA)-functionalized polypeptides with dopamine-modified polypeptides. This method allows for precise drug release at the tumor site, taking advantage of the unique characteristics of the tumor environment for targeted therapy.

Newsletter Subscribe

Subscribe to get the latest articles and insights directly in your inbox.